Retrospective study assessing neutralizing antibody responses against Sars-Cov-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 01 Feb 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition